- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, September 22, 2023
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article published in the March 2016 issue of The American Journal of Managed Care® (AJMC®) was cited in 2 pieces online this week. Yahoo! published “Are Your Hospital Outpatient Department Costs Too High? A Doctor's Office May Help” and Healthcare Finance published “Costs for Common Healthcare Procedures Higher in Hospital Outpatient Departments,” both referencing the findings in “National Estimates of Price Variation by Site of Care” that prices for services performed at hospital outpatient departments were higher than in physician offices.
The National Pharmaceutical Council’s CER Daily Newsfeed for September 19, 2023, highlighted a video interview published on AJMC.com, the website of AJMC. “Dr Ryan Haumschild Discusses Payer, Provider Perspectives on Prior Authorization in Rare Diseases” featured AJMC editorial board member Ryan Haumschild, PharmD, MS, MBA, director of pharmacy at Emory Winship Cancer Institute, sharing his unique perspectives as both a provider and payer on the use of prior authorizations.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bimekizumab Shows Promising 52-Week Safety and Efficacy in Psoriatic Arthritis
May 3rd 2024Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.
Read More
